Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Ascendis’ TransCon PTH shows promise in phase 2 hypoparathyroidism trial

pharmaceutical-business-reviewApril 22, 2020

Tag: Ascendis Pharma , TransCon PTH , hypoparathyroidism

PharmaSources Customer Service